Global Nanotechnology in Drug Delivery Market - 2022-2029

Market Overview

Nanotechnology in Drug Delivery Market size was valued US$ 51.4 billion in 2021 and is estimated to reach US$ 203.6 billion by 2029, growing at a CAGR of 17.9% during the forecast period (2022-2029).

Nanotechnology in drug delivery is the rapidly developing way of providing effective treatment for various diseases. Nanotechnology-based drugs can potentially deliver the drugs to targeted and affected parts of the human body by reducing the side effects. Nanotechnology drug delivery utilizes the nanoscale range nanoparticles like liposomes, chemotherapeutic agents, biological agents, etc., to deliver the therapeutic agents to specifically targeted sites in a controlled manner. The nanotechnology drug delivery has certain benefits, including improving the ability to deliver poorly water-soluble drugs, reduce drug accumulation within healthy tissue, combine therapeutic and diagnostic modalities through one agent, transportation of drugs across epithelial and endothelial barriers, protection from the biological environment, effective treatment can be achieved by retaining the drug in the body long time.

Market Dynamics

The global nanotechnology in drug delivery market is growing due to several factors such as rising demand for nanotechnology in drug delivery due to the increasing prevalence of chronic diseases, various new cost-effective product launches and novel technological advances.

Rising approvals of nanotechnology drug delivery and various new technological advancements are expected to drive market growth.

The market is driven by the rising prevalence of chronic ailments like cancer, tumor, heart disease, coronary artery disease due to unhealthy life styles and changing environments worldwide. According to the World Health Organization, in 2020, Cancer is the leading cause of death, accounting for 9.6 million people who died worldwide, and more than 300000 patients are being diagnosed each year. Nanomedicine plays a vital role in enhancing human health by reducing side effects. Currently, nanotechnology-based drug delivery statins, nano antibiotics, and other agents can be utilized as a valid treatment for preventing certain diseases like cancer, coronary artery disease, and many others. Nanoantibiotics will utilize this effect to enhance infection treatment via the application of both nanoparticles with antimicrobial therapies and nanosized biological molecules for improved antibiotic drug delivery.

There is a rise in FDA approvals. A surge in innovative drugs through extensive research and developments in various diseases has created ample opportunity for this market. For instance, on 17th June 2020, Nanobiotix Company received feedback on developing effective designed platinum-based chemotherapy from the US FDA. The Company had started to advance Phase III clinical trials to treat neck and head cancer based on chemistry, manufacturing, and controls (CMC) development through necessary study design to support the future New Drug Application (NDA).

Concerns associated with nanotechnology in drug delivery is expected to hamper the market growth.

Increasing environmental concerns as nanotechnology procedure are not environment friendly that can lead to critical environmental hazards. Usage of chemicals for extraction of nanoparticles will add up in polluting environment. Health related concern is also a factor that can restraint the growth of market.

Industry Analysis

The global nanotechnology in drug delivery market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis.

Segment Analysis

Applications segment is expected to hold the largest market share in global nanotechnology in drug delivery market

The global nanotechnology in the drug delivery market is segmented based on technology, applications, and region.

In terms of technology type, the global nanotechnology in the drug delivery market is bifurcated into micelles, nanoparticles, liposomes, nanocrystals, etc. The nanoparticles segment has the highest market share due to the increasing launching of advanced technology-based nanoparticles for effective treatment and avoiding the side effects due to harmful drugs. For instance, on 5th Nov 2019, MIT engineers developed the nanoparticle coated with "right-handed" molecules to enhance drug delivery.

Depending on technology type, micelles, nanoparticles, liposomes, nanocrystals segments are also growing faster due to increasing the demand for effective treatment drugs with the rising new nano-based medicine. For instance, on 14th May 2020, NanOlogy Company had been launched a new drug delivery injection Nanopac for targeting the treatment of Pancreatic Cancer and Mucinous Cystic Neoplasms.

Depending on the applications, global nanotechnology in the drug delivery market is divided into anti-infective, neurology, anti-inflammatory/immunology, oncology, cardiovascular/physiology, and others. Among these, the anti-inflammatory/immunology segment had the highest share in 2019. This is primarily due to rising investment in developing new drugs for the immune system for various diseases. For instance, Ventus launched with $60 million from Versant Ventures and GV. Working out of dual headquarters in Waltham and Montreal, the biotech plans to create drugs that target the immune system's first defense line, known as the innate immune system. For instance, on 6th May 2020, Ventus Therapeutics Company received USD 60 Million in funding to develop medicines that have been targeted the innate immune system.

Similarly, anti-infective, neurology, oncology, cardiovascular/physiology segments are also growing faster due to the increase in the prevalence of chronic ailments like cancer, cardiovascular, neurological diseases, etc., the globe. According to the World Health Organization, an estimated 31% of all global deaths, around 17.9 million people, die each year due to cardiovascular diseases. This propels the advanced treatment methods for treating the diseases through the nanotechnology drug delivery systems.

Geographical Analysis

North America region holds the largest market share in the global nanotechnology in drug delivery market

By region, the global Nanotechnology in the Drug Delivery market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America is the dominant region for global nanotechnology in the drug delivery market. It is expected to grow at the highest CAGR during the forecasted period due to leading healthcare players with advanced technology followed by the European region. Furthermore, the rising prevalence of chronic diseases like cancer, cardiovascular, etc., in this region due to unhealthy lifestyles and diet has propelled nanotechnology's demand in the drug delivery market. According to a recent study by American Cancer Society researchers, in the United, 750000 cases were diagnosed, at least 42% of cancers cases in 2020. This propels the demand for the electronics avionics market during the forecast period.

The Asia Pacific is also growing faster for nanotechnology in the drug delivery market, owing to the prevalence of chronic diseases like cancer, cardiovascular, etc. According to the Cancer Organization in 2020, the Asia Pacific region has accounted for around 5.9 million cases were diagnosed and is projected to reach around 7.8 million new cancer cases by 2050. This will propel the demand for advanced treatment for drug delivery through nanotechnology.

Competitive Landscape

The global nanotechnology in the drug delivery market is highly competitive with several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Ceramisphere Health Pvt Limited, Cristal Therapeutics, CYTIMMUNE SCIENCES, Inc., Nanobiotix, NanoCarrier Co. Ltd., NanOlogy LLC, EnColl Corporation, EyePoint Pharmaceuticals, AbbVie Inc., Aquanova AG, BlueWillow Biologics, Camurus AB, Celgene, Inc., Lena Nanoceutics Ltd. are the leading market players with significant market share.

There is rising FDA approval for adopting advanced technology like nanotechnology to treat various chronic diseases like cancer, cardiovascular diseases, etc. has created a huge opportunity for this market. For instance, on 9th June 2020, NanOlogy Company had started clinical trials using nanotechnology-based drug delivery devices like intratumoral (IT) injections of NanoPac to treat lung cancer with FDA permission. Companies are entering into collaborations, acquisitions, mergers, and licensing for increasing their market penetration.

Key players focus on various strategic initiatives such as merger & acquisition, geographical expansion, new product launches, and increasing R&D expenditure to stay competitive. For instance, in May 2021, Nanobiotix and Lianbio announced their partnership to develop first in class radio-enhancer NBTXR3 over therapeutic combination in Asian markets.

Key Companies to Watch

AbbVie Inc:

Overview: AbbVie is America-based biopharmaceutical company that is publicly traded. It was founded in 2013 and is headquartered in Illinois, United States. Due to the spin-off of Abbott Laboratories it was originated. It is research based pharmaceutical manufacturer.

Product Portfolio:

Leupron Depot: It is injectable gonadotropin releasing hormone medication used for management of endometriosis and pain relief.

Key Developments: In March 2022, Abbvie announced its acquisition of Syndesi Therapeutics for $1 billion.

The global nanotechnology in drug delivery market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.